Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Labels

March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
rareconnect.org TMAU

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :
https://forms.gle/vem2TjepKobYZPBu8

current participants : 113 (update 18dec20)

Wednesday, August 26, 2009

Pubmed paper 2009 : Actions of Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3

Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3
http://www.ncbi.nlm.nih.gov/pubmed/19665535

Regular readers will know that FMO3 enzyme is always of special interest to the blog. This is the latest pubmed paper about the enzyme, albeit only in a limited way.

The testers were testing the phase1 xenobiotic metabolizing enzymes to see how they are affected by natural medicines used by Cree Indians in Canada.Normally when researchers check reactions in phase 1 xenobiotic metabolizing enzymes, they only check the Cytochrome P450 super-family, even though the FMO family come into this category. This is probably because at the moment the FMO enzymes are perceived as unimportant. So it was good to see FMO3 tested in this test as well.

Probably the main reason for interest in these enzymes is that drugs are metabolized by them, and they can also have an inhibitive or inducing effect on the enzymes. Probably one priority to pharmaceutical industry testers is the thought of lawsuits. These enzymes have only been properly known about for about 50 years, and so a lot has still to be learnt about them, especially the FMO family. Presumably the tests were done 'in vitro' at a lab, rather than 'in vivo'.

The 'textbook' definition of FMO enzymes will say it can neither be induced or inhibited, even though those using the same definition have found a compound in cruciferous vegetables to be very inhibitive. In this study, FMO3 seemed to be 'middling' inhibited by the plant extracts used. However, it's not known how conclusive such studies can be, since often there are other conflicting papers published. Perhaps the 'behaviour' of a xenobiotic metabolizing enzyme isn't accepted until a definite trend in papers is seen.

Herbs and spices are of special interest in FMO3 because most are likely FMO3 'substrates' and also may have an inhibitive/inducing effect (currently unknown). This may explain why when taking herbs/spices/medicines, some may feel 'strange' and perhaps get pain around the liver (since the liver is the most prominent place where such enzymes are based).



body odor

concepts:
phase1 : modify a compound
phase2 : add a molecule to a compound; conjugate

These enzymes deal with internally produced compounds (neurotransmitters, hormones etc) as well as external compounds (from diet and environment etc)

The most abundant area for these enzymes is the liver, but they are everywhere.

0 comments:

Post a Comment